Dr. Carla Martins-Furness

Carla Martins-Furness is a biomedical researcher specializing in cancer pharmacology and metal-based therapeutics. Her work centers on the development and mechanistic evaluation of copper coordination complexes as potential anticancer agents, with a strong focus on molecular pathways governing apoptosis and cellular stress responses in solid tumors.

Her publications investigate the effects of novel copper complexes in pancreatic, breast, and colorectal cancer models. These studies demonstrate induction of intrinsic apoptotic pathways through mitochondrial disruption, reactive oxygen species generation, and modulation of key regulators such as p53, HMOX1, and inhibitor of apoptosis proteins. This research highlights the therapeutic potential of targeting redox balance and stress-response signaling to overcome drug resistance.

Although the current body of published work is limited, it reflects a coherent and technically rigorous research program. Martins-Furness contributes to advancing metal-based drug design by linking chemical structure to biological activity, offering promising lead compounds and mechanistic insights relevant to translational oncology.